Pharmaceuticals News and Research

RSS

Celanese EVA Performance Polymers, PSI partner to develop drug-eluting devices

Particle Sciences Inc., a leading pharmaceutical CRO, and Celanese EVA Performance Polymers, a leading supplier of ethylene vinyl acetate into pharmaceutical applications, are working together to streamline the development of drug-eluting devices.

29 Apr 2011

Iroko Pharmaceuticals announces acquisition of iCeutica

Iroko Pharmaceuticals, LLC today announces that it has acquired iCeutica, Inc. to further strengthen Iroko's position as the leading developer of novel, low-dose non-steroidal anti-inflammatory drugs.

29 Apr 2011

UIC receives federal contract to develop antibiotics against three bacterial infections

Researchers at the University of Illinois at Chicago's Center for Pharmaceutical Biotechnology have been awarded a federal contract for up to $13.8 million to develop antibiotics to treat anthrax, tularemia and plague.

28 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

GE Healthcare reaches agreement to acquire Applied Precision

GE Healthcare, a unit of General Electric Company, today announced it has reached an agreement to acquire Applied Precision, Inc., a supplier of innovative cellular imaging technologies for the fast-growing cell biology and biomedical research sectors.

28 Apr 2011

Nautic Partners announces acquisition of Omnicare Clinical Research

Nautic Partners LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has acquired Omnicare Clinical Research from Omnicare, Inc. Headquartered in King of Prussia, PA, Omnicare CR is a full-service, global clinical research organization.

28 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

Merck, Inspire announce expiration of HSR waiting period for cash tender offer

Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR") has expired in connection with the previously announced cash tender offer made by Monarch Transaction Corp., a wholly owned subsidiary of Merck, to purchase all of the outstanding shares of common stock of Inspire.

28 Apr 2011

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.

28 Apr 2011

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

28 Apr 2011

Leading pharmaceutical company, Flamel enter Micropump license agreement

Flamel Technologies announced today that it has entered into a license agreement with a leading specialty pharmaceutical company for development and commercialization of two molecules for pain indications.

28 Apr 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO Pharmaceuticals, Inc. today reviewed key first quarter accomplishments and reported consolidated financial results for the first quarter of 2011.

28 Apr 2011

Justices question Vermont's effort to restrict drug data mining

During Tuesday's oral arguments, the justices suggested that the state law, which restricts pharmaceutical marketers' ability to obtain data on doctor prescribing habits, may violate free-speech rights.

28 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

AstraZeneca announced today the launch of "click-to-chat" on CRESTOR.com and PurplePill.com. The new "click-to-chat" technology gives consumers an option to contact a live AstraZeneca customer service representative with just a click of a button.

28 Apr 2011

Panel speakers to discuss hepatitis C prevention, treatment at Mayes College event

Mayes College of Healthcare Business and Policy at University of the Sciences is hosting a panel discussion on hepatitis C prevention and treatment, on Thursday, April 28, 2011, from 5 to 7 p.m.

28 Apr 2011

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies, for some of the 6,000 rare diseases that afflict 25 million Americans.

28 Apr 2011

Janssen, Beactica enter drug discovery agreement

Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV.

28 Apr 2011

Kava tea may cause kidney failure and muscle breakdown

When a 34-year-old bicyclist was found collapsed on a roadside and rushed to the University of Rochester Medical Center emergency room on the verge of kidney failure and muscle breakdown, doctors were surprised to discover that a trendy tea derived from the kava plant was the cause of his ills.

28 Apr 2011

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

ProtoKinetix, is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market.

27 Apr 2011